Darunavir/Cobicistat (Prezcobix)
The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mu...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015 Jul, 2015
|
Series: | Common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mutations (RAMs) |
---|---|
Physical Description: | 1 online resource illustrations |